Zydus Lifesciences Limited

Here are the headlines.

8.69 lakh cancer deaths prompt Zydus $75 million acquisition.

1.8% hiring growth contrasts with 9.4% salary increases.

$240 billion in trade awaits interim deal between India and America.

This growing burden creates urgent demand for effective treatments, but it also signals a massive commercial opportunity for pharmaceutical companies capable of developing complex biologic medicines.

Two major players are positioning themselves at the forefront of this shift.

Zydus Lifeficiences is expanding its oncology business through biosimilars and international manufacturing partnerships.

The company recently launched a Nivoluma biosimilar in India with pricing starting near Rs 14,000.

Now in India, the same fight is playing out very differently.

Zydus didn't want to wait for a deal and it launched its own Progetta copy in 2024 and Roche took it to court.

Now, one of Roche's Indian patents doesn't cover the medicine itself.

It covers a method of making it.

And that creates a problem for Roche.

To prove Zydus copied its method, Roche first needs to know how Zydus makes its drug.

But that's Zydus' secret.

Indian law does offer a way around this.

And yes, if you talk about biologics, um, Biocon, Syngene, uh, they are some of the big players in the biologics space, right? But I think we still don't have enough novel biologics, uh, company in India.

I think, again, a special mention to Zomato.

I think they have, uh, an antibody drug in phase one, uh, clinical trial.

It's a novel drug, first in class.